The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
Open accessAbstract
The RNA-dependent RNA polymerase of the severe acute respiratory syndrome coronavirus 2 is an important target in current drug development efforts for the treatment of coronavirus disease 2019. Molnupiravir is a broad-spectrum antiviral that is an orally bioavailable prodrug of the nucleoside analogue β-D-N 4 -hydroxycytidine (NHC). Molnupiravir or NHC can increase G to A and C to U transition mutations in replicating coronaviruses. These increases in mutation frequencies can be linked to increases in antiviral effects; however, biochemical data of molnupiravir-induced mutagenesis have not been reported. Here we studied the effects of the active compound NHC 5'-triphosphate (NHC-TP) against the purified severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase complex. The efficiency of incorporation of natural nucleotides over the efficiency of incorporation of NHC-TP into model RNA substrates followed the order GTP (12,841) > ATP (424) > UTP (171) > CTP (30), indicating that NHC-TP competes predominantly with CTP for incorporation. No significant inhibition of RNA synthesis was noted as a result of the incorporated monophosphate in the RNA primer strand. When embedded in the template strand, NHC-monophosphate supported the formation of both NHC:G and NHC:A base pairs with similar efficiencies. The extension of the NHC:G product was modestly inhibited, but higher nucleotide concentrations could overcome this blockage. In contrast, the NHC:A base pair led to the observed G to A (G:NHC:A) or C to U (C:G:NHC:A:U) mutations. Together, these biochemical data support a mechanism of action of molnupiravir that is primarily based on RNA mutagenesis mediated via the template strand.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Physiological concentrations of purines and pyrimidines
Traut, T. W. (1994) · Molecular and Cellular Biochemistry · doi:10.1007/bf00928361 · Cited by 1,867
Sheahan, T. P., Sims, A. C., Zhou, S., Graham, R. L., Pruijssers, A. J., Agostini, M. L., Leist, S. R., Schäfer, A., Dinnon, K. H., Stevens, L. J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb5883 · Cited by 1,071
Gordon, C. J., Tchesnokov, E. P., Woolner, E., Perry, J. K., Feng, J. Y., Porter, D. P., & Götte, M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013679 · Cited by 985
Self-citationGordon, C. J., Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ac120.013056 · Cited by 850
Self-citationThe broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
Crotty, S., Maag, D., Arnold, J. J., Zhong, W., Lau, J. Y. N., Hong, Z., Andino, R., & Cameron, C. E. (2000) · Nature Medicine · doi:10.1038/82191 · Cited by 820
Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M. (2019) · Viruses · doi:10.3390/v11040326 · Cited by 622
Self-citationSmith, E. C., Blanc, H., Vignuzzi, M., & Denison, M. R. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003565 · Cited by 444
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
Wahl, A., Gralinski, L. E., Johnson, C. E., Yao, W., Kovarova, M., Dinnon, K. H., Liu, H., Madden, V. J., Krzystek, H. M., De, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03312-w · Cited by 409
Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA
Ferron, F., Subissi, L., Silveira De Morais, A. T., Le, N. T. T., Sevajol, M., Gluais, L., Decroly, E., Vonrhein, C., Bricogne, G., Canard, B., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718806115 · Cited by 404
Painter, W. P., Holman, W., Bush, J. A., Almazedi, F., Malik, H., Eraut, N. C. J. E., Morin, M. J., Szewczyk, L. J., & Painter, G. R. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02428-20 · Cited by 397
Cited by
Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.
Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., Kovalchuk, E., Gonzalez, A., Delos Reyes, V., Martín-Quirós, A., Caraco, Y., Williams-Diaz, A., Brown, M. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116044 · Cited by 1,857
Therapeutic strategies for COVID-19: progress and lessons learned
Li, G., Hilgenfeld, R., Whitley, R., & De Clercq, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00672-y · Cited by 676
Malone, B., Urakova, N., Snijder, E. J., & Campbell, E. A. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00432-z · Cited by 530
Fischer, W. A., Eron, J. J., Holman, W., Cohen, M. S., Fang, L., Szewczyk, L. J., Sheahan, T. P., Baric, R., Mollan, K. R., Wolfe, C. R., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl7430 · Cited by 529
Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines
Fernandes, Q., Inchakalody, V. P., Merhi, M., Mestiri, S., Taib, N., Moustafa Abo El-Ella, D., Bedhiafi, T., Raza, A., Al-Zaidan, L., Mohsen, M. O., et al. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2031274 · Cited by 447
Metadata
- Authors
- Gordon, C. J., Tchesnokov, E. P., Schinazi, R. F., & Götte, M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 297
- Issue
- 1
- Pages
- 100770
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W3163488943
- Cited by
- 293
- References
- 31
- FWCI
- 18.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. https://app.cochat.ai/papers/10.1016/j.jbc.2021.100770
- The paper
- Gordon, C. J., Tchesnokov, E. P., Schinazi, R. F., & Götte, M. (2021). Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2021.100770
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.